Liraglutide reduced fat droplet accumulation and scarring in diabetic heart tissue by activating an energy-sensing pathway that improved mitochondrial function and reduced oxidative stress.
Fibrosis reversedLiraglutide reduced TGF-β1 and collagen I/III expression in diabetic heart models via AMPK activation
What the researchers found
Liraglutide significantly reduced lipid droplet accumulation and myocardial fibrosis in both cell and mouse models of diabetic cardiomyopathy. The drug decreased expression of fibrosis markers TGF-β1, collagen I, and collagen III. It achieved these protective effects by activating AMPK, which improved mitochondrial function, boosted antioxidant gene expression, enhanced insulin signaling, and reduced oxidative stress in heart cells.
Why it matters
Diabetic cardiomyopathy is a major cause of heart failure in people with diabetes, and there are currently no specific approved treatments for it. This study reveals a detailed molecular mechanism by which liraglutide — already used for diabetes and obesity — could protect the heart from diabetes-related damage, potentially adding cardioprotection to its existing benefits.
The numbers in context
Decreased TGF-β1, collagen I, collagen III · Increased AMPK activation · Improved mitochondrial function · Reduced oxidative stress · Both in vitro and in vivo models
How the study worked
Combined cell culture and animal study. Differentiated H9c2 heart cells were treated with high glucose and free fatty acids to mimic diabetic conditions, then treated with liraglutide. A mouse model of diabetic cardiomyopathy was created using high-fat diets. Both models assessed lipid droplet formation, fibrosis markers, AMPK signaling, mitochondrial function, antioxidant gene expression, and oxidative stress.
Who was studied
H9c2 cardiomyocyte cell line and C57BL/6 mice with diet-induced diabetic cardiomyopathy
What this study cannot tell us
This is a preclinical study using cell lines and mice, not human patients. The H9c2 cells are rat-derived and may not fully represent human cardiomyocyte biology. The molecular mechanisms identified need to be validated in human cardiac tissue. The study does not report functional cardiac outcomes (e.g., ejection fraction, cardiac output).
How to read the evidence
This is a preclinical study combining cell culture and animal experiments. While it provides valuable mechanistic insight into how liraglutide protects the heart, the findings need human clinical validation before they can inform treatment decisions.
When this study was published
Published in 2025, this study reflects current research into the cardioprotective mechanisms of GLP-1 drugs, an area of intense investigation following positive cardiovascular outcomes in clinical trials.
The bigger picture
GLP-1 receptor agonists have already shown cardiovascular benefits in large clinical trials, reducing heart attacks and strokes. This study helps explain one mechanism behind those benefits — direct protection of heart muscle cells from the metabolic damage of diabetes. Understanding these pathways could lead to more targeted cardiac therapies.
Questions still open
- Does this AMPK-mediated cardiac protection occur at the doses used in human diabetes treatment?
- Would liraglutide reverse established diabetic cardiomyopathy, or only prevent its development?
- How do other GLP-1 drugs (semaglutide, tirzepatide) compare in their cardiac protective mechanisms?
Common questions
What is diabetic cardiomyopathy?
How does liraglutide protect the heart from diabetes damage?
Read the original research
The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy.
Cellular and molecular life sciences : CMLS, 82(1), 39
Citation
Kuo, Chien-Yin; Tsou, Sing-Hua; Kornelius, Edy; Chan, Kuei-Chuan; Chang, Kai-Wei; Li, Jung-Chi; Huang, Chien-Ning; Lin, Chih-Li. (2025). The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy.. Cellular and molecular life sciences : CMLS, 82(1), 39. https://doi.org/10.1007/s00018-024-05558-9